KF-26777

KF-26777

Clinical data
Other names	KF-26777
Identifiers
IUPAC name (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one
CAS Number	206129-88-6^Y
PubChem CID	9820916
ChemSpider	7996665
UNII	N33070GI64
ChEMBL	ChEMBL2181965
CompTox Dashboard (EPA)	DTXSID101028432
Chemical and physical data
Formula	C16H18BrN5O
Molar mass	376.258 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCN(C2=O)C1N=C(c(cc3)ccc3Br)NC1C=4N2CCN=4
InChI InChI=1S/C16H16BrN5O/c1-2-8-21-15-12(14-18-7-9-22(14)16(21)23)19-13(20-15)10-3-5-11(17)6-4-10/h3-6H,2,7-9H2,1H3,(H,19,20) Key:GYGNZJDWTHECQT-UHFFFAOYSA-N
(verify)

KF-26777 is a drug which acts as a potent and selective antagonist for the adenosine A₃ receptor, with sub-nanomolar affinity (A₃ Ki=0.2nM) and high selectivity over the other three adenosine receptor subtypes.^[1] Simple xanthine derivatives such as caffeine and DPCPX have generally low affinity for the A₃ subtype and must be extended by expanding the ring system and adding an aromatic group to give high A₃ affinity and selectivity.^[2]

References

1. Saki M, Tsumuki H, Nonaka H, Shimada J, Ichimura M (May 2002). "KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist". European Journal of Pharmacology. 444 (3): 133–41. doi:10.1016/S0014-2999(02)01662-X. PMID 12063073.
2. Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). "Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility". Chemical Reviews. 108 (1): 238–63. doi:10.1021/cr0682195. PMID 18181659.